Literature DB >> 30723519

Ganglion Cell Complex Analysis as a Potential Indicator of Early Neuronal Loss in Idiopathic Intracranial Hypertension.

Geetha Athappilly1,2, Ignacio García-Basterra3, Flavia Machado-Miller1, Thomas R Hedges1, Carlos Mendoza-Santiesteban4, Laurel Vuong1.   

Abstract

Reliable visual field testing is the gold standard in identifying future vision loss in patients with Idiopathic Intracranial hypertension (IIH). However, when field performance is unreliable, GCC analysis may be useful. We evaluated IIH patients over three visits: initial visit, follow-up visit and a third visit, almost 1 year later. We evaluated mean deviation (MD), GCC and RNFL at presentation and the second visit and compared it to the mean deviation (MD) on fields at the third visit. As early as the second visit, GCC loss correlated with visual field results seen at the third visit.

Entities:  

Keywords:  Idiopathic Intracranial Hypertension (IIH); Optical Coherence Tomography (OCT); Papilledema; ganglion cell analysis; pseudotumor cerebri

Year:  2018        PMID: 30723519      PMCID: PMC6351016          DOI: 10.1080/01658107.2018.1476558

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  17 in total

1.  Effect of instructions on conventional automated perimetry.

Authors:  K E Kutzko; C F Brito; M Wall
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-06       Impact factor: 4.799

Review 2.  Diagnostic criteria for idiopathic intracranial hypertension.

Authors:  Deborah I Friedman; Daniel M Jacobson
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

3.  Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability.

Authors:  Peggy Auinger; Mary Durbin; Steven Feldon; Mona Garvin; Randy Kardon; John Keltner; Mark Kupersmith; Patrick Sibony; Kim Plumb; Jui-Kai Wang; John S Werner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-04       Impact factor: 4.799

4.  Intravitreal bevacizumab in the treatment of peripapillary choroidal neovascular membrane secondary to idiopathic intracranial hypertension.

Authors:  In-Jung Lee; Luke J Maccheron; Anthony S Kwan
Journal:  J Neuroophthalmol       Date:  2013-06       Impact factor: 3.042

5.  Causes and Prognosis of Visual Acuity Loss at the Time of Initial Presentation in Idiopathic Intracranial Hypertension.

Authors:  John J Chen; Matthew J Thurtell; Reid A Longmuir; Mona K Garvin; Jui-Kai Wang; Michael Wall; Randy H Kardon
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

6.  Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study.

Authors:  Maren Skau; Birgit Sander; Dan Milea; Rigmor Jensen
Journal:  J Neurol       Date:  2010-09-19       Impact factor: 4.849

7.  Functional visual loss in idiopathic intracranial hypertension.

Authors:  Joshua J Ney; Nicholas J Volpe; Grant T Liu; Laura J Balcer; Mark L Moster; Steven L Galetta
Journal:  Ophthalmology       Date:  2009-07-30       Impact factor: 12.079

8.  Quantitative analysis of optic nerve damage in idiopathic intracranial hypertension (IIH) at diagnosis.

Authors:  S Bianchi Marzoli; P Ciasca; M Curone; G Cammarata; L Melzi; A Criscuoli; G Bussone; D D'Amico
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

9.  Follow-up of mild papilledema in idiopathic intracranial hypertension with optical coherence tomography.

Authors:  Gema Rebolleda; Francisco J Muñoz-Negrete
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-14       Impact factor: 4.799

10.  Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT.

Authors:  Falko Kaufhold; Ella Maria Kadas; Christoph Schmidt; Hagen Kunte; Jan Hoffmann; Hanna Zimmermann; Timm Oberwahrenbrock; Lutz Harms; Konrad Polthier; Alexander U Brandt; Friedemann Paul
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

View more
  6 in total

1.  Optical coherence tomography use in idiopathic intracranial hypertension.

Authors:  Kiran Malhotra; Tanyatuth Padungkiatsagul; Heather E Moss
Journal:  Ann Eye Sci       Date:  2020-03-15

2.  The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes.

Authors:  Mark Thaller; Victoria Homer; Yousef Hyder; Andreas Yiangou; Anthony Liczkowski; Anthony W Fong; Jasvir Virdee; Rachel Piccus; Marianne Roque; Susan P Mollan; Alexandra J Sinclair
Journal:  J Neurol       Date:  2022-10-15       Impact factor: 6.682

3.  Accuracy of a Deep Learning System for Classification of Papilledema Severity on Ocular Fundus Photographs.

Authors:  Caroline Vasseneix; Raymond P Najjar; Xinxing Xu; Zhiqun Tang; Jing Liang Loo; Shweta Singhal; Sharon Tow; Leonard Milea; Daniel Shu Wei Ting; Yong Liu; Tien Y Wong; Nancy J Newman; Valerie Biousse; Dan Milea
Journal:  Neurology       Date:  2021-05-19       Impact factor: 9.910

4.  Chorioretinal abnormalities in idiopathic intracranial hypertension: case reports.

Authors:  Leonardo E Ariello; Luiz Guilherme Marchesi Mello; Sérgio Luis Gianotti Pimentel; Mário L R Monteiro
Journal:  Int J Retina Vitreous       Date:  2022-07-22

5.  Optical coherence tomography features and correlation of functional and structural parameters in patients of idiopathic intracranial hypertension.

Authors:  Mousumi Banerjee; Swati Phuljhele; Gunjan Saluja; Pawan Kumar; Rohit Saxena; Pradeep Sharma; Deepti Vibha; Awadh Kishor Pandit
Journal:  Indian J Ophthalmol       Date:  2022-04       Impact factor: 2.969

6.  Change in contrast sensitivity and OCT parameters in idiopathic intracranial hypertension.

Authors:  Obaidur Rehman; Parul Ichhpujani; Ekta Singla; Reetika Negi; Suresh Kumar
Journal:  Ther Adv Ophthalmol       Date:  2022-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.